'Endocrine therapy' diaporamas de présentation

DISSECTING THE DECISION Optimizing the Use of CDK4/6 Inhibitors in the Management of

DISSECTING THE DECISION Optimizing the Use of CDK4/6 Inhibitors in the Management of ER-Positive, HER2-Negative Metastatic Breast Cancer. Co-Chairs. Neil Love, MD Sara M Tolaney, MD, MPH. Faculty. Neelima Denduluri , MD Shom Goel , BMedSci, MBBS, PhD Erika Hamilton, MD Komal Jhaveri , MD

1.95k views • 194 slides

New Approaches to the Treatment of Breast Cancer

New Approaches to the Treatment of Breast Cancer. Richard G. Pestell, MD, PhD Kimmel Cancer Center Jefferson University Hospitals. INCTR 6th Annual meeting Chennai, India. Unique Point in History. www.cnn.com. Overview. Epidemiology Current therapies

1.18k views • 98 slides

Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, MA

Clinical Updates Hormonally Sensitive, Early-Stage Breast Cancer. Current Considerations in the Management of Patients with Hormonally Sensitive Early-stage Breast Cancer. Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, MA. Overview.

980 views • 85 slides

PHARMACY TECHNICIAN

1.07k views • 62 slides

SABCS 2012

SABCS 2012. Guy Jerusalem, MD, PhD. SABCS 2012: Clinical studies in HER2 negative disease. Hunderds of oral and poster presentations to be covered (endocrine therapy , chemo , targeted therapy )

720 views • 56 slides

516 views • 50 slides

Adjuvant Breast Cancer Therapy An Analysis of Current Treatment Paradigms

Adjuvant Breast Cancer Therapy An Analysis of Current Treatment Paradigms. Mark D. Pegram, MD UCLA/Jonsson Comprehensive Cancer Center. Age 47 Premenopausal breast carcinoma Lumpectomy - 1.3 cm poorly differentiated, high grade infiltrating ductal carcinoma

828 views • 41 slides

How can I help you? (or frequently asked questions)

How can I help you? (or frequently asked questions). Adam Stacey-Clear Consultant Breast and Endocrine Surgeon. Who gets breast cancer?. Age Sex Where you live Family history Genetics Social class and alcohol. How common?. Incidence - 1 in 12 80% in women over 50 Very rare under 35.

462 views • 38 slides

Details Of Use Of These Slides

Should clinicians routinely recommend trastuzumab (Herceptin) as part of the adjuvant therapy for all patients with Her2 positive early breast cancer? A review of recent data, and reflections on how these results relate to the use of Adjuvant!. Details Of Use Of These Slides

553 views • 37 slides

A Case Based Approach to Hormone Therapy

Clinical Updates Optimizing Endocrine Therapy for Early Breast Cancer. A Case Based Approach to Hormone Therapy. Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, CA. Case 1.

574 views • 34 slides

Clinical Research

708 views • 31 slides

A summary of SGIS CRG policy, strategy and initial draft recommendations to NHS England

A summary of SGIS CRG policy, strategy and initial draft recommendations to NHS England. Presented by Dr John Dean. SGIS CRG, 20 th March 2014. Policy 1.

408 views • 29 slides

2007 UPDATE OF ASCO RECOMMENDATIONS FOR THE USE OF TUMOR MARKERS IN BREAST CANCER

2007 UPDATE OF ASCO RECOMMENDATIONS FOR THE USE OF TUMOR MARKERS IN BREAST CANCER Clinical Practice Guideline. Introduction. ASCO convened an Update Committee to review and update recommendations for the use of tumor markers in breast cancer.

523 views • 26 slides

Objectives

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy with Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.

427 views • 25 slides

Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)

Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE). Metastatic Breast Cancer 10% of breast cancer. 30+ patients per year in Colchester All incurable but median survival 2 to 3 years with current therapy

284 views • 16 slides

Sino-Danish Breast Cancer Research Centre

206 views • 11 slides

Sino-Danish Breast Cancer Research Centre

217 views • 11 slides

Management of Triple-Negative Breast Cancer

Management of Triple-Negative Breast Cancer. Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center San Antonio, Texas. Three Treatment Options for Breast Cancer. Surgery Radiotherapy

1.18k views • 10 slides

Albain KS et al. Lancet Oncol 2010;11(1):55-65. Albain KS et al.

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer on Chemotherapy: A Retrospective Analysis of a Randomised Trial. Albain KS et al. Lancet Oncol 2010;11(1):55-65. Albain KS et al.

403 views • 9 slides

Martin M et al. Proc SABCS 2012;Abstract S1-7.

220 views • 7 slides